On Wednesday, Shares of Bank of America Corporation (NYSE:BAC), lost -1.30% to $17.46.
Bank of America Corp. has named co-heads of its health-care investment banking team in the Americas, according to a memo obtained by The Wall Street Journal and confirmed by a spokesman.
The bank has poached Credit Suisse’s health-care investment banking co-head Charlie Newton to run the group alongside Brian McCarthy, the memo says.
The changes come in the midst of a deal boom where global M&A could surpass historic highs. Health-care deal making has been the biggest driver of M&A, with companies pairing up at an unprecedented clip.
Bank of America has advised on some of the largest health-care transactions during this deal boom. Last year, it advised Allergan on its sale to Actavis, which ranked the year’s largest deal. It also advised Omnicare on its sale to CVS Health. The Wall Street Journal Reports
Bank of America Corporation is a bank holding company. The company, through its auxiliaries, operates through Consumer and Business Banking; Consumer Real Estate Services; Global Wealth and Investment Administration; Global Banking; Global Markets; and Other segments.
Shares of Kinross Gold Corporation (NYSE:KGC), inclined 4% to $2.08, during its last trading session, as mining and related stocks get a jolt from the rise in safe haven demand.
Gold prices gained Wednesday as the uncertain outlook for the Chinese economy supported demand for a metal that is considered a hedge against risk.
The most actively traded contract, gold for December delivery, recently raised $9.2, or 0.8%, to trade at $1,126.10 a troy ounce on the Comex division of the New York Mercantile Exchange.
Kinross Gold Corporation, together with its auxiliaries, engages in the acquisition, exploration, and development of gold bearing properties. It is involved in mining and processing gold and silver ores. The company’s gold production and exploration activities are carried out principally in Canada, the United States, the Russian Federation, Brazil, Chile, Ghana, and Mauritania.
Finally, Omeros Corporation (NASDAQ:OMER), ended its last trade with -10.03% loss, and closed at $22.52, despite positive phase 2 news. The company declared additional positive data in the it’s phase 2 clinical trial of OMS721 for the treatment of thrombotic microangiopathies (TMAs).
TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) – aggregations of platelets – in the microcirculation of the body’s organs, most commonly the kidney and brain. OMS721 is Omeros’ lead human monoclonal antibody in its mannan-binding lectin-associated serine protease-2 (MASP-2) program for the treatment of TMAs, counting atypical hemolytic uremic syndrome (aHUS).
The Phase 2 trial is designed to enroll primarily aHUS patients but can also enroll patients with thrombotic thrombocytopenic purpura (TTP) and hematopoietic stem cell transplant (HSCT)-related TMA. The trial has fully enrolled the first and second cohorts and is presently concluding the third and final planned cohort of its dose-ranging stage. In each three-patient cohort, OMS721 is dosed for four weeks. Data from the first (low-dose) cohort were released on February 19, 2015. Recently the company is releasing data from its second (mid-dose) cohort and data to date from its third (high-dose) cohort.
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. It markets Omidria for use during cataract surgery or intraocular lens, or replacement surgery.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
